KUALA LUMPUR, Feb 27 (Bernama) — Public-listed healthcare company, Malaysian Genomics Resource Centre Berhad (MGRC), and its subsidiary, pathology services company Clinipath (Malaysia) Sdn Bhd (Clinipath) today announced the availability of affordable, fast-turnaround, liquid biopsy tests developed by CIRCULOGENE Diagnostics LLC for doctors in Malaysia.
Liquid biopsies offer a non-invasive, quick, cheaper and safer, complement to surgical biopsies. They can provide real-time and actionable information about a tumour including which treatments, especially targeted therapies, are available for a particular patient. CIRCULOGENE’s CLIA/CAP-certified liquid biopsy tests examine cell-free nucleic acids to provide full genomic load analysis of somatic and germline mutations, DNA and RNA, and immunotherapy biomarkers all from a single standard tube of blood. This testing enables accurate and real-time data to help doctors and their patients choose the best available targeted therapies and available clinical trials, monitor efficacy and monitor for recurrence.